
The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.
Han, C., Altwerger, G., Menderes, G., Bellone, S., Bianchi, A., Yadav, G., Lopez, S., Manzano, A., Ratner, E.S., Azodi, M., Litkouhi, B., Silasi, D.A., Huang, G.S., Schwartz, P.E., Santin, A.D.Volume:
154
Langue:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2019.04.084
Date:
June, 2019
Fichier:
PDF, 59 KB
english, 2019